See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Invesco S&P SmallCap Health Care ETF (PSCH) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Invesco S&P SmallCap Health Care ETF (PSCH) - free report >>
Image: Bigstock
Healthcare ETF (PSCH) Hits New 52-Week High
For investors seeking momentum, Invesco S&P SmallCap Health Care ETF (PSCH - Free Report) is probably on radar. The fund just hit a 52-week high, and is up about 77% from its 52-week low price of $83.54/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
PSCH in Focus
This fund targets the small-cap segment of the broad healthcare space. It offers exposure to companies engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies. The fund charges investors 29 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The broad healthcare sector has been an area to watch lately given the excitement over signs of a first successful late-stage COVID-19 vaccine trial. Pfizer (PFE) in collaboration with German drugmaker BioNTech SE announced that their vaccine candidate was more than 90% effective in preventing COVID-19 based on initial data from a large study.
More Gains Ahead?
Currently, PSCH has a Zacks ETF Rank #3 (Hold) with a Medium risk outlook. Therefore, it is hard to get a handle on its future returns one way or the other. However, many of the segments that make up this ETF have a strong Zacks Industry Rank. So, there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>